Conference Description
Biotherapeutics, including protein and nucleic acid-based therapeutics, cell and gene therapies, and vaccines, play an important role in maintaining and improving global public health which is particularly critical in the face of public health crises such as the COVID-19 pandemic. They are also being developed to treat a wide variety of serious medical conditions including infectious diseases, cancer, auto-immune, cardio-vascular, gastro-intestinal and neurological disorders. The development of biotherapeutics and vaccines, from candidate engineering and selection, through expression, purification, formulation, analytical characterization and finally delivery to patients, is a highly inter-disciplinary scientific field.
The second Gordon Research Conference on Biotherapeutics and Vaccines Development in 2021 will bring together scientists from academia, industry, government, and non-profit organizations for in depth exploration of the latest cutting-edge advances in this rapidly moving, exciting field. This GRC aims to assemble researchers from a variety of fields to discuss and debate in an open forum the fundamental scientific issues underlying the development and manufacturing of biotherapeutics and vaccines. The program will reflect the broad cross-disciplinary scientific and engineering issues involved in the development of biotherapeutics and vaccines. Tentative sessions include: a keynote session featuring talks on emerging concepts and trends by thought leaders in the field; drug engineering and candidate selection; applications of artificial intelligence/machine learning in development and manufacturing; cell culture and expression; novel modalities including cell and gene therapies; identification and control of critical quality attributes; downstream purification and flexible manufacturing; and formulation and drug product screening.
To encourage participation by junior scientists at the graduate and postdoctoral level, a Gordon Research Seminar (GRS) will be held immediately prior to the GRC. The GRS will be an exciting opportunity for junior scientists to present posters on their latest research and engage with colleagues in a supportive, interactive environment.
The topics, speakers, and discussion leaders for the conference sessions are displayed below. The conference chair is currently developing their detailed program, which will include the complete meeting schedule, as well as the talk titles for all speakers. The detailed program will be available by July 14, 2021. Please check back for updates.
Keynote Session: The Future of Vaccines and Biotherapeutics Development
Discussion Leaders
-
Peter Tessier (University of Michigan, USA)
-
Jessica Molek (GlaxoSmithKline, USA)
Speakers
-
Jorg Thommes (Bill & Melinda Gates Medical Research Institute, USA)
-
Peter Marks (Food and Drug Administration, USA)
Therapeutic Engineering and Optimization
Discussion Leaders
-
Gunasekaran Kannan (Denali Therapeutics, USA)
-
Veysel Kayser (University of Sydney, Australia)
Speakers
-
Randal Ketchem (Just – Evotec Biologics, USA)
-
Mihalis Kariolis (Denali Therapeutics, USA)
-
Charlotte Deane (University of Oxford, United Kingdom)
-
Laurence Fayadat_Dilman (Merck & Co., USA)
AI and Big Data in Development and Manufacturing
Discussion Leaders
-
Theodore Randolph (University of Colorado Boulder, USA)
-
Cenk Undey (Amgen, USA)
Speakers
-
Christopher Calderon (Ursa Analytics, USA)
Cell Culture and Expression
Discussion Leaders
-
Christina Alves (Biogen, USA)
-
Trent Munro (University of Queensland, Australia)
Speakers
-
Jennitte Stevens (Amgen, USA)
-
Gavin Barnard (Genentech, USA)
-
Christopher Love (Massachusetts Institute of Technology, USA)
Properties of Biologics Impacting Safety and Efficacy
Discussion Leaders
-
Tim Menzen (Coriolis Pharma, Germany)
-
William Weiss IV (Eli Lilly and Company, USA)
Speakers
-
John Beals (Eli Lilly & Co., USA)
-
Vibha Jawa (Bristol Myers Squibb, USA)
-
Keith Chappell (University of Queensland, Australia)
-
Daniela Verthelyi (Food and Drug Administration, USA)
Early-Career Investigator Presentations
Discussion Leaders
-
Maria-Monica Castellanos (GlaxoSmithKline, USA)
-
John Schardt (University of Michigan, USA)
Speakers
Downstream Purification
Discussion Leaders
-
Mark Brower (Merck & Co., USA)
-
Todd Przybycien (Rensselaer Polytechnic Institute, USA)
Speakers
-
Raquel Aires-Barros (Instituto Superior Técnico, Portugal)
-
Sally Kline (Genentech, USA)
-
John Mattila (Regeneron, USA)
-
Andrew Zydney (Pennsylvania State University, USA)
Formulation, Drug Product and Delivery
Discussion Leaders
-
Christian Schoneich (University of Kansas, USA)
-
Ping Yeh (EirGenix, Inc., Taiwan)
Speakers
-
John Marino (National Institute of Standards and Technology, USA)
-
Olivier Mozziconacci (Merck & Co., USA)
-
Satish Singh (Moderna, USA)
Novel Therapeutic Modalities
Discussion Leaders
-
Zenobia Taraporewala (Food and Drug Administration, USA)
-
Ran Zhang (Orchard Therapeutics, United Kingdom)
Speakers
-
Daniel Kaufman (University of California, San Diego, USA)
-
Alison Moore (Allogene Therapeutics, USA)
-
Anne De Groot (EpiVax, Inc., USA)
-
Aravind Asokan (Duke University School of Medicine, USA)
The GRC Power Hour™
Organizers:
-
Jessica Molek (GlaxoSmithKline, USA)
-
Eva Chi (University of New Mexico, USA)
